MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the ...

Overseas markets are central to MiniMed’s business, accounting for 70% of reported net sales in the company’s 2026 financial ...

MiniMed MMED recently announced the commercial launch of its MiniMed 780G automated insulin delivery system integrated with Abbott Laboratories' ABT Instinct sensor and the MiniMed Go system ...

The MarketWatch News Department was not involved in the creation of this content. NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack ...

NORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced results from a new randomized crossover study demonstrating that ...

Medtronic has earned FDA approval that will allow it to broaden the scope of its MiniMed 780G system portfolio. FDA has cleared Medtronic’s SmartGuard algorithm as an interoperable automated glycemic ...

As Medtronic begins rolling out a recently FDA-cleared diabetes management system combining its MiniMed 780G insulin pump and Abbott’s Instinct glucose sensor, the medtech giant has launched a new ...

GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...

Medtronic plc MDT has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s ABT Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the ...

MiniMed anticipates the commercial launch of the MiniMed™ 780G system with Instinct sensor in the first European countries during the summer. The company will be presenting the full system at the 19th ...